CXCL8 and hypoalphalipoproteinemia, primary, 1: Based on the network pharmacological analysis, 9 hug targets (CCL2, IL10, PTGS2, TNF, MAPK1, IL6, CXCL8, TP53, and VEGFA) were collected and validated as the therapeutic targets of FHD on NS in vivo.